Keji Biomedical

CARsgen Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative CAR-T cell therapies for the treatment of hematologic malignancies and solid tumors. The company has established a comprehensive pipeline targeting various antigens, including BCMA, CD19, CLDN18.2, and GPC3. Its lead product, zevorcabtagene autoleucel (CT053), has received approval in China for the treatment of relapsed or refractory multiple myeloma. CARsgen is a global leader in developing CAR-T therapies for solid tumors, with its Claudin 18.2-targeted candidate, satricabtagene autoleucel (CT041), being the first of its kind to enter a confirmatory Phase 2 clinical trial. The company utilizes proprietary technology platforms such as CycloCAR and THANK-uCAR to enhance the efficacy and safety of its cell therapies. CARsgen operates integrated research, development, and manufacturing facilities in both Shanghai, China, and North Carolina, USA.